HighTower Advisors
RPRX icon

HighTower Advisors’s Royalty Pharma RPRX Stock Holding History

HighTower Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16M Sell
285,630
-7,291
-2% -$379K 0.02% 734
2026
Q1 		$14.1M Buy
292,921
+11,799
+4% +$517K 0.01% 741
2025
Q4 		$10.9M Buy
281,122
+61,166
+28% +$2.33M 0.01% 832
2025
Q3 		$7.76M Buy
219,956
+13,842
+7% +$501K 0.01% 956
2025
Q2 		$7.43M Buy
206,114
+34,720
+20% +$1.15M 0.01% 923
2025
Q1 		$5.34M Sell
171,394
-2,017
-1% -$63.9K 0.01% 1018
2024
Q4 		$4.42M Sell
173,411
-9,177
-5% -$243K 0.01% 1099
2024
Q3 		$5.15M Sell
182,588
-13,624
-7% -$377K 0.01% 1022
2024
Q2 		$5.17M Sell
196,212
-28,212
-13% -$782K 0.01% 992
2024
Q1 		$6.82M Buy
224,424
+49,028
+28% +$1.45M 0.01% 837
2023
Q4 		$4.93M Sell
175,396
-55,748
-24% -$1.53M 0.01% 978
2023
Q3 		$6.26M Buy
231,144
+69,527
+43% +$2.07M 0.01% 830
2023
Q2 		$4.97M Sell
161,617
-2,454
-1% -$83.1K 0.01% 908
2023
Q1 		$5.9M Buy
164,071
+5,118
+3% +$190K 0.01% 784
2022
Q4 		$6.29M Sell
158,953
-8,848
-5% -$369K 0.01% 761
2022
Q3 		$6.74M Buy
167,801
+792
+0.5% +$33.8K 0.02% 689
2022
Q2 		$7.02M Buy
167,009
+15,303
+10% +$627K 0.02% 684
2022
Q1 		$5.92M Buy
151,706
+20,430
+16% +$802K 0.01% 811
2021
Q4 		$5.24M Buy
131,276
+10,861
+9% +$422K 0.01% 879
2021
Q3 		$4.36M Buy
120,415
+2,008
+2% +$78K 0.01% 883
2021
Q2 		$4.85M Buy
+118,407
New +$5.04M 0.01% 801

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors's RPRX Position: Q2 2026 in Review

HighTower Advisors reduced its Royalty Pharma (RPRX) stake by 2.5% in Q2 2026, selling an estimated $379K and leaving 285,630 shares worth $16M. The position accounts for 0.02% of the portfolio, ranked #734.

HighTower Advisors first reported a position in RPRX in Q2 2021 and has held it in 21 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • HighTower Advisors held 285,630 shares of Royalty Pharma worth $16M as of Q2 2026.
  • HighTower Advisors sold 7,291 Royalty Pharma shares in Q2 2026, an estimated $379K.
  • Royalty Pharma made up 0.02% of HighTower Advisors's portfolio in Q2 2026, its #734 holding.
  • HighTower Advisors first reported a position in Royalty Pharma in Q2 2021 and has held it in 21 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.